MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
its plans at the Oppenheimer healthcare conference. The company said it expects strong growth from its main products. These include Afrezza for children, the FUROSCIX autoinjector, and a new drug program, MNKD-201, for lung disease (IPF). Even though there may be competition from United Therapeutics, MannKind's leaders said they feel positive about the future. The company hopes to exceed $450 million in revenue by 2026. It expects growth from Afrezza, FUROSCIX, and royalties from Tyvaso DPI. The company also believes it could receive $700 million to $1 billion in cash from Tyvaso over the next few years. MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets Copyright: dolgachov / 123RF Stock Photo Afrezza may soon be approved for children, with a decision expected on May 29. The company is also testing a smaller dose to make it easier for kids to use. FUROSCIX is expected to grow, especially in hospitals, and the new autoinjector could help sales. MNKD-201 i
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind (MNKD) had its price target lowered by Wedbush from $10.00 to $8.00. They now have an "outperform" rating on the stock.MarketBeat
- MannKind to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- MannKind to Participate in Upcoming Investor ConferencesGlobeNewswire
- MannKind (MNKD) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c)" to "sell (d+)".MarketBeat
- MannKind at Oppenheimer: 2025 Revenue Jumps 46%, Eyes $450M+ in 2026 on Afrezza and FUROSCIX [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 2/26/26 - Beat
MNKD
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- MNKD's page on the SEC website